Vertex Pharmaceuticals Inc. is betting $80 million up front plus up to $490 million in milestones on a new avenue for addressing pulmonary pathology developed by Parion Sciences Inc., that could potentially improve the treatment of cystic fibrosis (CF) and other lung diseases.